Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type Segment
1.1.1.2. Drug Class
1.1.1.3. Route of Administration
1.1.1.4. Distribution Channel
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objective
1.4.1. Objective 1
1.4.2. Objective2
1.4.3. Objective 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing Prevalence of Aspergillosis
3.4.2. Advancements in Medical Research
3.4.3. Awareness and Diagnosis Improvement
3.5. Market Restraint Analysis
3.5.1. Limited Treatment Options
3.5.2. High Treatment Costs
3.6. Industry Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Aspergillosis Treatment Market: By Type Segment Analysis
4.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
4.2. Allergic Aspergillosis
4.2.1. Allergic Aspergillosis Market, 2018 – 2030 (USD Million)
4.3. Chronic Aspergillosis
4.3.1. Chronic Aspergillosis Market, 2018 – 2030 (USD Million)
4.4. Invasive Aspergillosis
4.4.1. Invasive Aspergillosis Market, 2018 – 2030 (USD Million)
Chapter 5. Aspergillosis Treatment Market: Drug Class Segment Analysis
5.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
5.2. Antifungal Drugs
5.2.1. Antifungal Drugs Market, 2018 – 2030 (USD Million)
5.2.1.1. Azoles
5.2.1.2. Echinocandins
5.2.1.3. Polyenes
5.2.1.4. Allylamines
5.2.1.5. Others
5.3. Others
5.3.1. Others Market, 2018 – 2030 (USD Million)
Chapter 6. Aspergillosis Treatment Market: Route of Administration Segment Analysis
6.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
6.2. Oral Drugs
6.2.1. Oral Drugs Market, 2018 – 2030 (USD Million)
6.3. Ointments
6.3.1. Ointments Market, 2018 – 2030 (USD Million)
6.4. Powders
6.4.1. Powders Market, 2018 – 2030 (USD Million)
6.5. Others
6.5.1. Others Market, 2018 – 2030 (USD Million)
Chapter 7. Aspergillosis Treatment Market: By Distribution Channel Segment Analysis
7.1. Aspergillosis Treatment: Market Share Analysis, 2022 & 2030
7.2. Hospital Pharmacy
7.2.1. Hospital Pharmacy Market, 2018 – 2030 (USD Million)
7.3. Retail Pharmacy
7.3.1. Retail Pharmacy Market, 2018 – 2030 (USD Million)
7.4. Others
7.4.1. Others Market, 2018 – 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Aspergillosis Treatment Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. North Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Competitive Scenario
8.2.2.3. Regulatory Framework
8.2.2.4. U.S. Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Competitive Scenario
8.2.3.3. Regulatory Framework
8.2.3.4. Canada Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.3. Europe
8.3.1. Europe Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.3.2. UK
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. UK Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Germany Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. France Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Italy Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Regulatory Framework
8.3.6.4. Spain Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Regulatory Framework
8.3.7.4. Denmark Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Regulatory Framework
8.3.8.4. Sweden Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Regulatory Framework
8.3.9.4. Norway Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. Japan Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. China Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. India Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.4.5. Australia
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Australia Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.4.6. Thailand
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Thailand Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.4.7. South Korea
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. South Korea Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Competitive Scenario
8.5.2.4. Regulatory Framework
8.5.2.5. Brazil Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Mexico Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Argentina Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. South Africa Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. Saudi Arabia Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. UAE Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. Kuwait Aspergillosis Treatment Market, 2018 – 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Market Share Analysis, 2022
9.4. Company Profiles/Listing
9.4.1. Pfizer, Inc
9.4.1.1. Overview
9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Merck & Co
9.4.2.1. Overview
9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. F2G
9.4.3.1. Overview
9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Novartis AG;
9.4.4.1. Overview
9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Astellas Pharma Inc
9.4.5.1. Overview
9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Bayer AG
9.4.6.1. Overview
9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Mayne Pharma Group Limited
9.4.7.1. Overview
9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. PULMATRiX
9.4.8.1. Overview
9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer